Evropska unija - islandščina - EMA (European Medicines Agency)

viiv healthcare b.v. - dolutegravir járn, áhrif - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - dovato er ætlað fyrir meðferð hiv veira tegund 1 (hiv-1) sýkingu í fullorðnir og unglingar ofan 12 ára aldri vega á minnst 40 kg, með engin þekkt eða grun andstöðu við integrase hemil flokki, eða áhrif.

Evropska unija - islandščina - EMA (European Medicines Agency)

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - sýklalyf - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.

Evropska unija - islandščina - EMA (European Medicines Agency)

viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults,  adolescents and children  weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.

Evropska unija - islandščina - EMA (European Medicines Agency)

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

Evropska unija - islandščina - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients 3 years of age and older (see sections 4. 2, 4. 4 og 5.

Evropska unija - islandščina - EMA (European Medicines Agency)

gilead sciences ireland uc - ledipasvir, sofosbuvir - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 og 5. fyrir lifrarbólgu c veira (hcv) arfgerð-sérstakur starfsemi sjá kafla 4. 4 og 5.

Evropska unija - islandščina - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (sjá kafla 4. 2, 4. 4 og 5.

Evropska unija - islandščina - EMA (European Medicines Agency)

janssen-cilag international n.v.    - rilpivirin hýdróklóríð - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - edurant, ásamt öðrum antiretroviral lyf, er ætlað fyrir meðferð hiv veira tegund 1 (hiv‑1) sýkingu í andretróveirumeðferð‑barnalegt sjúklingar 12 ára og eldri með veiru hlaða ≤ 100,000 hiv‑1 rna afrit/ml. eins og með aðrar antiretroviral lyf, arfgerðar mótstöðu prófa ætti að fylgja því að nota edurant.

Evropska unija - islandščina - EMA (European Medicines Agency)

qbiotics netherlands b.v. - tigilanol tiglate - tigilanol tiglate - hundar - fyrir meðferð ekki resectable, ekki sjúklingum (sem sviðsetning) undir húð mastur klefi æxli staðsett á eða fjarlæga að olnboga eða skuldir, og ekki resectable, ekki sjúklingum húð mastur klefi æxli í hunda.

Evropska unija - islandščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - Æxlishemjandi lyf - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.